[go: up one dir, main page]

WO2002074288A3 - Composés chimiques - Google Patents

Composés chimiques Download PDF

Info

Publication number
WO2002074288A3
WO2002074288A3 PCT/GB2002/001220 GB0201220W WO02074288A3 WO 2002074288 A3 WO2002074288 A3 WO 2002074288A3 GB 0201220 W GB0201220 W GB 0201220W WO 02074288 A3 WO02074288 A3 WO 02074288A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
sexual dysfunction
tetrahydrobenz
ssri
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/001220
Other languages
English (en)
Other versions
WO2002074288A2 (fr
Inventor
John Blundell Hutchison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Priority to AU2002246228A priority Critical patent/AU2002246228A1/en
Publication of WO2002074288A2 publication Critical patent/WO2002074288A2/fr
Publication of WO2002074288A3 publication Critical patent/WO2002074288A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'une quantité suffisante du composé (I) dans la fabrication d'un médicament destiné au traitement d'une dysfonction sexuelle chez un patient en train ou sur le point de subir un traitement avec un inhibiteur sélectif de recaptage de la sérotonine. L'invention concerne également l'utilisation d'une quantité suffisante du composé (I) et de l'un au moins des inhibiteurs de recaptage de la sérotonine pour la fabrication d'un médicament destiné au traitement de la dépression sans induire de dysfonction sexuelle.
PCT/GB2002/001220 2001-03-15 2002-03-15 Composés chimiques Ceased WO2002074288A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002246228A AU2002246228A1 (en) 2001-03-15 2002-03-15 Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106446.8A GB0106446D0 (en) 2001-03-15 2001-03-15 Chemical compounds
GB0106446.8 2001-03-15

Publications (2)

Publication Number Publication Date
WO2002074288A2 WO2002074288A2 (fr) 2002-09-26
WO2002074288A3 true WO2002074288A3 (fr) 2003-02-27

Family

ID=9910774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001220 Ceased WO2002074288A2 (fr) 2001-03-15 2002-03-15 Composés chimiques

Country Status (3)

Country Link
AU (1) AU2002246228A1 (fr)
GB (1) GB0106446D0 (fr)
WO (1) WO2002074288A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
EP1653966A1 (fr) * 2003-07-16 2006-05-10 Pfizer Limited Traitement des dysfonctionnements sexuels
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2686480A1 (fr) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh Nouveaux sels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633023A2 (fr) * 1993-06-10 1995-01-11 Eli Lilly And Company Prévention de l'émésis et traitement de la dysfunctionnement sexuelle par des tétrahydro(CD)indole-6-carboxamides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633023A2 (fr) * 1993-06-10 1995-01-11 Eli Lilly And Company Prévention de l'émésis et traitement de la dysfunctionnement sexuelle par des tétrahydro(CD)indole-6-carboxamides
US5703112A (en) * 1993-06-10 1997-12-30 Eli Lilly And Company Method of preventing emesis using tetrahydrobenz CD!indole-6-carbonxamides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BEERS M H AND BERKOW R: "The Merck Manual", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002215956 *

Also Published As

Publication number Publication date
WO2002074288A2 (fr) 2002-09-26
GB0106446D0 (en) 2001-05-02
AU2002246228A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
JP2005532372A5 (fr)
EP2298810A3 (fr) Traitement des troubles associés au TND alpha
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
BE2012C040I2 (fr)
WO2004039325A3 (fr) Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation
PT1387681E (pt) Compostos antivirais
WO2002094196A3 (fr) Methode de traitement de cancers associes a des niveaux de her-2 eleves
JP2004537500A5 (fr)
WO2002074288A3 (fr) Composés chimiques
EP1254668A3 (fr) Combinaison d'un inhibiteur de la recapture de la sérotonine et d'un GABA-A alpha 2/3 agoniste pour l'utilisation dans l'anxiété et la dépression
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
WO2003015690A3 (fr) Methode de traitement de l'insomnie primaire
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
AP1896A (en) The method of treating cancer
WO2006002096A3 (fr) Faibles doses de l-citrulline pour traiter des maladies
GEP201606538B (en) Preoperative treatment of post operative pain
WO2004037233A3 (fr) Utilisation d'inhibiteurs de la glycogene phosphorylase pour le traitement de maladies cardio-vasculaires
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
GB0111497D0 (en) Therapeutic methods
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
EP1260221A3 (fr) Therapie de combinaison de la depression et de l'anxieté

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP